SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Sorrento
Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today it will present the
clinical data for Cynviloq™ (IG-001), which resulted in its
approval as 1st line treatment of ovarian cancer by
Korean FDA in March of 2013. Highlights of the findings include
proof of non-inferiority of Cynviloq vs. Taxol in combination
therapy with Carboplatin in patients with advanced epithelial
ovarian cancer.
These data will be presented at the AACR conference on Advances
in Ovarian Cancer Research: From Concept to Clinic, Miami, FL on Friday,
September 20, 2013 12:30 p.m.
– 2:30 p.m. at the Met Ballroom 5-7,
Poster Session B, Poster Board #B67. The presentation is entitled:
"IG-001 — A Non-biologic Nanoparticle Paclitaxel for the Treatment
of Ovarian Cancer" authored by: Larn Hwang, Catherine Cheng, and Vuong Trieu.
About Cynviloq™
Cynviloq (or IG-001; a
paclitaxel-loaded micellar diblock copolymer) is a next-generation
branded paclitaxel formulation for the potential treatment of
metastatic breast cancer, non-small cell lung cancer, pancreatic
cancer, and other solid tumors. In July, the FDA Division of
Oncology Products 1 agreed that the data available are sufficient
to support a 505(b)(2) pathway, using Abraxane® and Taxol® as the
Reference Listed Drugs, to obtain approval. Sorrento anticipates initiating the single
Bioequivalence trial required for registration, in the fourth
quarter of 2013.
Sorrento has exclusive
distribution rights to Cynviloq in the U.S. and the 27 countries of
the European Union, from Samyang Biopharmaceuticals, a South Korean
corporation.
About Sorrento Therapeutics, Inc.
Sorrento
Therapeutics, Inc. is a publicly-traded, development-stage
biopharmaceutical company engaged in the acquisition, discovery,
development and commercialization of proprietary drug therapeutics
for addressing significant unmet medical needs in the Unites
States, Europe and additional
international markets. Sorrento's
therapeutic focus is oncology, but is also developing therapeutic
products for inflammation, metabolic, and infectious diseases.
Sorrento's proprietary G-MAB®
fully-human antibody library platform was designed to facilitate
the rapid identification and isolation of highly specific antibody
therapeutics. In addition, Sorrento is developing proprietary ADCs as
well as AfDCs combining its G-MAB® antibodies with anti-tumor
agents.
More information is available at
www.sorrentotherapeutics.com.
Forward-Looking Statements
This press release
contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Words such as "assumes," "plans," "believes,"
"expects," "anticipates," and "will," and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements include statements about the preclinical and clinical
development of Sorrento's human
antibody therapeutics. All such forward-looking statements are
based on Sorrento's current
beliefs and expectations, and should not be regarded as a
representation by Sorrento that
any of its plans will be achieved. Actual results may differ
materially from those set forth in this press release due to the
risks and uncertainties inherent in Sorrento's businesses; the potential for
approval and commercial success of Cynviloq; the scope and validity
of patent protection for Sorrento's platform technologies, and the risk
that the development or commercialization of product candidates may
infringe the intellectual property rights of others; the potential
that Sorrento may require
substantial additional funding in order to obtain regulatory
approval for and commercialize Sorrento's proprietary G-MAB® fully-human
antibody library platform technologies or product candidates; and
additional risks set forth in Sorrento's filings with the Securities and
Exchange Commission. These forward-looking statements represent
Sorrento Therapeutics' judgment as of the date of this release. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Sorrento
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. This caution
is made under the safe harbor provisions of Section 21E of the
Private Securities Litigation Reform Act of 1995.
Genexol-PM® is a registered trademark of Samyang Corporation;
Abraxane® is a registered trademark of Celgene, Inc; Taxol® is a
registered trademark of Bristol-Myers Squibb, Inc.
SOURCE Sorrento Therapeutics, Inc.